Asarina Pharma AB (publ) Interim Report Q1 2020 released
Asarina Pharma CEO Peter Nordkild: “In April 2020 we released inconclusive topline results from our phase IIb study in PMDD. Although disappointing, these results do not invalidate our 40 years’ research into allopregnanolone and Sepranolone. Allopregnanolone remains implicated in a wide range of stress- and compulsion-related disorders, from Tourette to menstrual migraine to OCD, PTSD, compulsive gambling, addiction and more. As the endogenous compound that modulates the body’s allopregnanolone levels, our novel treatment Sepranolone remains a driving scientific and commercial force for us.